Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR): Cytogenetic Abnormalities and Gene Mutations.

Objectives: Acute myeloid leukemia, myelodysplasia-related (AML-MR) is a particularly aggressive and adverse subtype of acute myeloid leukemia, predominantly affecting older adults who often face complex treatment challenges and poor prognoses. The majority of AML-MR patients fail to achieve remission, leading to significantly reduced overall survival rates. In light of these dire outcomes, staying informed about the most recent advancements in AML-MR research and clinical practice is imperative. This review examines the latest World Health Organization classifications of AML-MR, highlighting this disease's prevalent mutations and cytogenetic abnormalities. Furthermore, we explore recent therapeutic developments, including the introduction of targeted therapies and hypomethylating agents, which offer promising avenues for improving patient outcomes. The reclassification of AML-MR underscores the critical role of genetic profiling in elucidating its pathology and guiding therapeutic strategies. Future research should focus on developing personalized treatment approaches that address the intricate genetic and clinical complexities of AML-MR, aiming to enhance survival rates and improve the quality of life for affected patients.